

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2015 Navy **Date:** March 2014

Appropriation/Budget Activity 1319: <i>Research, Development, Test & Evaluation, Navy / BA 5: System Development & Demonstration (SDD)</i>	R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>
--	--

COST (\$ in Millions)	Prior Years	FY 2013	FY 2014	FY 2015 Base	FY 2015 OCO #	FY 2015 Total	FY 2016	FY 2017	FY 2018	FY 2019	Cost To Complete	Total Cost
Total Program Element	53.579	37.426	28.458	8.287	-	8.287	9.935	9.586	9.353	9.601	Continuing	Continuing
0933: <i>Medical/Dental Equipment Dev</i>	18.765	8.464	9.458	8.287	-	8.287	9.935	9.586	9.353	9.601	Continuing	Continuing
9999: <i>Congressional Adds</i>	34.814	28.962	19.000	-	-	-	-	-	-	-	-	82.776

The FY 2015 OCO Request will be submitted at a later date.

A. Mission Description and Budget Item Justification

The purpose of this budget item is to develop biomedical equipment and related techniques to reduce morbidity; to enhance the logistic feasibility of modern medical care for combat casualties; to sustain casualties for evacuation to fixed medical facilities for definitive care; and to ensure that personnel are medically qualified for military duty. There is a strong potential for dual use, technology transfer, and biotechnology firms/industry participation in the projects.

B. Program Change Summary (\$ in Millions)	FY 2013	FY 2014	FY 2015 Base	FY 2015 OCO	FY 2015 Total
Previous President's Budget	14.880	9.458	9.643	-	9.643
Current President's Budget	37.426	28.458	8.287	-	8.287
Total Adjustments	22.546	19.000	-1.356	-	-1.356
• Congressional General Reductions	-	-			
• Congressional Directed Reductions	-	-			
• Congressional Rescissions	-	-			
• Congressional Adds	-	19.000			
• Congressional Directed Transfers	-	-			
• Reprogrammings	-1.600	-			
• SBIR/STTR Transfer	-1.155	-			
• Program Adjustments	-	-	-0.261	-	-0.261
• Rate/Misc Adjustments	-	-	-1.095	-	-1.095
• Congressional General Reductions	-3.699	-	-	-	-
Adjustments					
• Congressional Add Adjustments	29.000	-	-	-	-

Congressional Add Details (\$ in Millions, and Includes General Reductions)

Project: 9999: *Congressional Adds*

Congressional Add: *Military Dental Research*

FY 2013	FY 2014
5.992	6.000

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2015 Navy		Date: March 2014	
Appropriation/Budget Activity 1319: <i>Research, Development, Test & Evaluation, Navy / BA 5: System Development & Demonstration (SDD)</i>		R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>	
Congressional Add Details (\$ in Millions, and Includes General Reductions)		FY 2013	FY 2014
Congressional Add: <i>Wound Care Research (transferred from Defense Health Program)</i>		12.983	13.000
Congressional Add: <i>NAMRU Research</i>		9.987	-
Congressional Add Subtotals for Project: 9999		28.962	19.000
Congressional Add Totals for all Projects		28.962	19.000

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2015 Navy										Date: March 2014		
Appropriation/Budget Activity 1319 / 5					R-1 Program Element (Number/Name) PE 0604771N / Medical Development				Project (Number/Name) 0933 / Medical/Dental Equipment Dev			
COST (\$ in Millions)	Prior Years	FY 2013	FY 2014	FY 2015 Base	FY 2015 OCO #	FY 2015 Total	FY 2016	FY 2017	FY 2018	FY 2019	Cost To Complete	Total Cost
0933: Medical/Dental Equipment Dev	18.765	8.464	9.458	8.287	-	8.287	9.935	9.586	9.353	9.601	Continuing	Continuing
Quantity of RDT&E Articles	0.000	-	-	-	-	-	-	-	-	-		
# The FY 2015 OCO Request will be submitted at a later date.												
A. Mission Description and Budget Item Justification												
The purpose of this budget item is to develop biomedical equipment and related techniques to reduce morbidity; to enhance the logistic feasibility of modern medical care for combat casualties; to sustain casualties for evacuation to fixed medical facilities for definitive care; and to ensure that personnel are medically qualified for military duty. Each work unit undertaken in this project has a military requirement. Efforts are justified based upon military payoff and cost benefit. There is a strong potential for dual use, technology transfer, and biotechnology firms/industry participation in the projects.												
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)									FY 2013	FY 2014	FY 2015	
Title: Tactical Logistics Planning Tool Articles: FY 2013 Accomplishments: OCO Tactical Medical Logistics Planning Tool (TML+) - A research tool that models patient flow from the point of injury through definitive care, and an analysis tool that supports OCO operational risk assessment, field medical services planning and systems analysis. Because it can handle larger amounts of data, TML+ provides the capability to model medical treatment facilities at all levels of care and their respective functional areas, the number and type of personnel, and the type, speed, and capacity of transportation assets. The plan is to continue to develop specific modeling capabilities in TML+ to support the development of OCO medical plans that optimize clinical outcomes for combat casualties using the minimum amount of manpower, materiel, and CASEVAC/Enroute care resources. FY 2013 Accomplishments: Drafted certification plan for TML to operate on government networks (med, NMCI, OneNet). Initiated update of treatment profiles. FY 2014 Plans: N/A FY 2015 Plans: N/A									0.040	-	-	
									-	-	-	
Title: Combat Trauma Registry - Expeditionary Medical Encounter Database (CTR EMED)									0.040	-	-	
Articles:									-	-	-	

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2015 Navy			Date: March 2014		
Appropriation/Budget Activity 1319 / 5		R-1 Program Element (Number/Name) PE 0604771N / Medical Development		Project (Number/Name) 0933 / Medical/Dental Equipment Dev	
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)			FY 2013	FY 2014	FY 2015
FY 2013 Accomplishments: OCO: Tactical Medical Logistics Planning Tool (TML+)- Tri-service database of all battle injuries, non-battle injuries, disease, and mental health encounters that occur in deployed medical treatment facilities supporting OCO. The CTR EMED tracks each casualty, develops a detailed injury profile of the casualty's injuries and severities in near real-time. The tactical, operational, and casualty clinical data are forwarded to the intelligence, materiel developer and threat mitigation communities. FY 2013 Accomplishments: Obtained FY13 IRB approval and drafted required DoD data use agreements.					
FY 2014 Plans: N/A					
FY 2015 Plans: N/A					
Title: Validation of the Human Surrogate (HS) Prototype			0.166	-	-
Articles:			-	-	-
FY 2013 Accomplishments: OCO: Human Surrogate Testing - Validation of the Human Surrogate (HS) Prototype will help determine the margin of safety of microwave counter Improvised Explosive Devices (IEDs) devices and munitions. The HS model, developed by Greenwave Scientific Inc., designed to be used to make accurate measurements of the specific absorption rate (SAR) of RF energy in the human body from Counter Radio-Controlled Electronic Warfare (CREW) devices. The absorption of radiofrequency (RF) by the human body is very complex. It is well known that even uniform RF exposures lead to non-uniform absorption in almost all human exposure situations. Current methods to measure SAR in the human body are elegant and elaborate processes but they can only be carried out in the laboratory. These consist of open and closed human phantom shells filled with liquids that simulate the electrical properties of human tissue. To measure the uneven absorption of RF energy a small electric field probe is mechanically moved around inside the phantom shell during exposure. FY 2013 Accomplishments: Developed and patented an acoustograph to directly measure RF energy in tissue. Drafted Technical Report in progress based on predicted energy absorption.					
FY 2014 Plans: N/A					
FY 2015 Plans:					

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2015 Navy			Date: March 2014		
Appropriation/Budget Activity 1319 / 5		R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>		Project (Number/Name) 0933 / <i>Medical/Dental Equipment Dev</i>	
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)			FY 2013	FY 2014	FY 2015
N/A					
Title: Laser Field Testing			0.278	-	-
Articles:			-	-	-
FY 2013 Accomplishments: OCO: Laser Field Testing - Based on a 5th Fleet Urgent Requirement, an evaluation of various commercial-off-the-shelf (COTS) and government-off-the-shelf (GOTS) Non-Lethal Weapons (NLW) technology is required to determine the effectiveness of a combined Acoustic and Laser device as a long range NLW hailing and warning device. The bioeffects effort will support legal, policy and treating development for these NLW devices and future acquisition to deploy these types of systems in-theatre. FY 2013 Accomplishments: Submitted Technical Report on operational field test measuring effectiveness of Laser and Acoustic hailers as communication devices for maritime security. Designed and assembled a bench apparatus for generating an extended laser glare source and superimposing the glare on visual cognitive/perceptual/memory tasks. FY 2014 Plans: N/A FY 2015 Plans: N/A					
Title: Medical/Dental Equipment Dev			7.940	9.458	8.287
Articles:			-	-	-
FY 2013 Accomplishments: Individualized Fatigue-Based Scheduling and Countermeasure System - Continued development of a tool that predicts, prevents, detects, and mitigates periods of high risk associated with fatigue. Coordinate with the Office of Naval Research to facilitate transition. USMC Suicide Prevention Program Resiliency Study and Related Efforts - Continued research leveraging the Marine Resiliency study and the execution of targeted studies of Marines. Continued assessments to include 12-month after deployment return to determine risk for chronic PTSD and potential factors for mitigation. Effort includes assessment of post-intervention efforts and psychological studies Intranasal Carbon Dioxide for Headache and Trigeminal Muscle Pain - Completed study supporting provision of an abortive migraine therapy with minimal side effects and high efficacy for use on deployment and in Military Treatment Facilities.					

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2015 Navy			Date: March 2014		
Appropriation/Budget Activity 1319 / 5		R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>		Project (Number/Name) 0933 / <i>Medical/Dental Equipment Dev</i>	
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)			FY 2013	FY 2014	FY 2015
Implementation of an Alternative Watchstanding Schedule on USN Surface Combatants - Continued data collection in support of a individualized fatigue-mitigated scheduling. Joint Development Projects with the Marine Corps Systems Command (MARCORSYSCOM) Medical Acquisition - Continued Joint Development Testing and Evaluation program for medical products and equipment. Finalizing development of casualty care systems for USMC Procurement. Human Factors Support of OWL Tool - Continued development of systems-design tool in support of the Individual Fatigue-Based Scheduling and Countermeasure System; coordinate fleet user survey; perform task analysis; assist Graphic User Interface (GUI) layout and design; collaborate on experimental design and coordinate fleet evaluation and testing. Intranasal Scopolamine for the Prevention of Motion Sickness in Dynamic Military Environments - Continued study for the prevention of motion sickness in dynamic military environments. Validation of Computerized Color Vision Tests for use in Naval Aviation - Continued data collection to validate two computer-based color vision tests that can isolate and classify red-green and yellow-blue color deficiencies and also quantify the loss of chromatic sensitivity. Biosurveillance Information Service (BIOSERV) - Continued data collection towards a central repository for open and DoD health surveillance data to provide a more robust picture of overall threats in an area. Field Friendly Rapid Blood Typing Capabilities to Support Role II Units - Completed initial Phase 1 Field Friendly Rapid Blood Typing Capabilities to Support Role II Units Counter Directed Energy Bio-effects: Completed coordinated test plan for medical device testing with China Lake NAS to test the vulnerability and susceptibility of first responder's medical devices to hostile directed energy environment. Wound Management Program: Continue to integrate efforts in wound closure, improve diagnostic measures and the treatment of heterotopic ossification. Mobile Oxygen Ventilation and External Suction (MOVES) Anesthesia - Continued to move toward completing development of MOVES anesthesia module to include test and evaluation and critical care certification. This device is a pre-planned product improvement for FRSS deployment for MTFs, Medicine Clinics, Corpsman, and Navy or USMC Special Operations. Joint effort to result in Marine Corps procurement. Malaria Vaccine for Military Personnel - Continued augmented efforts with the ongoing clinical trial effort to test, for safety and efficacy, a militarily relevant malaria vaccine regimen utilizing a promising novel vaccine candidate.					

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2015 Navy			Date: March 2014		
Appropriation/Budget Activity 1319 / 5		R-1 Program Element (Number/Name) PE 0604771N / Medical Development		Project (Number/Name) 0933 / Medical/Dental Equipment Dev	
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)			FY 2013	FY 2014	FY 2015
Non-recompressive therapies for decompression sickness (DCS): Initiated validation trials for a novel recompressive therapy for a disabled submarine scenario.					
FY 2014 Plans: Mobile Oxygen Ventilation and External Suction (MOVES) Anesthesia - Moving toward completing development of MOVES anesthesia module. This device is a pre-planned product improvement for Forward Resuscitative Surgery System (FRSS) deployment for MTFs, Medicine Clinics, Corpsman, and Navy or USMC Special Operations. Joint effort to result in Marine Corps procurement.					
Wound Management Program: Continue to integrate efforts in wound closure, improve diagnostic measures and the treatment of heterotopic ossification.					
Implementation of an Alternative Watchstanding Schedule on USN Surface Combatants - Complete data collection in support of a individualized fatigue-mitigated scheduling.					
Joint Development Projects with MARCORSYSCOM Medical Acquisition - Continue Joint Development Testing and Evaluation program for medical products and equipment. Finalize development for USMC Procurement.					
Individualized Fatigue-Based Scheduling and Countermeasure System - Complete research supporting development of a tool that predicts, prevents, detects, and mitigates periods of high risk associated with fatigue. Periods of high individualized performance risk will be predicted and prevented by providing individual, specific, and fatigue optimized schedules and mitigation strategies.					
Validation of Computerized Color Vision Tests for use in Naval Aviation - Complete validation two computer-based color vision tests that can isolate and classify red-green and yellow-blue color deficiencies and also quantify the loss of chromatic sensitivity.					
Malaria Vaccine for Military Personnel - Continue augmented efforts with the ongoing clinical trial effort to test, for safety and efficacy, a militarily relevant malaria vaccine regimen utilizing a promising novel vaccine candidate.					
Non-recompressive therapies for decompression sickness (DCS): Complete validation trials for a novel recompressive therapy for a disabled submarine scenario.					
Biosurveillance Information Service (BIOSERV) - Continue data collection towards a central repository for open and DoD health surveillance data to provide a more robust picture of overall threats in an area.					
Human Factors Support of OWL Tool - Complete development of systems-design tool in support of the Individual Fatigue-Based Scheduling and Countermeasure System; coordinate fleet user survey; perform task analysis; collaborate on experimental design and coordinate fleet evaluation and testing.					

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2015 Navy		Date: March 2014	
Appropriation/Budget Activity 1319 / 5	R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>	Project (Number/Name) 0933 / <i>Medical/Dental Equipment Dev</i>	
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)		FY 2013	FY 2014
Transition Projects from Force Health Protection Future Capability - Continue effort toward initiating Development, Testing, and Evaluation program for transition products from the Office of Naval Research 6.3 Advanced Development program. Focus is on transition of novel haemostatic agents (e.g. infusible haemostatic and field/first responder devices). FY 2015 Plans: Wound Management Program: Continue to integrate efforts in wound closure, improve diagnostic measures and the treatment of heterotopic ossification. Malaria Vaccine for Military Personnel - Complete augmented efforts with the ongoing clinical trial effort to test, for safety and efficacy, a militarily relevant malaria vaccine regimen utilizing a promising novel vaccine candidate. Biosurveillance Information Service (BioServ) - Complete training and develop maintenance plan. Joint Development Projects with MARCORSYSCOM Medical Acquisition - Continue Joint Development Testing and Evaluation program for medical products and equipment. Finalize development for USMC Procurement. Transition Projects from Force Health Protection Future Capability - Continue Development, Testing, and Evaluation program for transition products from the Office of Naval Research 6.3 Advanced Development program. Focus will be on transition of resuscitation agents, and mitigation of neurotrauma and post-traumatic stress.			
Accomplishments/Planned Programs Subtotals		8.464	9.458
C. Other Program Funding Summary (\$ in Millions) N/A			
Remarks			
D. Acquisition Strategy			
The acquisition strategy for product lines and products in the Medical Development Program is designed and implemented consistent with the particular product and with the nature and size of the investment. The Medical Development Program operates with a Memorandum of Understanding with the Marine Corps Systems Command (Family of Field Medical Equipment) for co-development of products for procurement by the USMC. The acquisition strategy for these products involved direct partnership with the acquisition and procurement professionals at Marine Corps Systems Command. The program's major Product Areas in the Medical Development Program are: 1) Equipment, 2) Pharmaceuticals/Biologics, and 3) Knowledge/Concepts. The primary Program Areas of Interest are in: 1) Expeditionary Medicine (Navy in Terrestrial, Maritime Surface, Submarine, & Aviation Operations), USMC in Expeditionary Operations. In these areas the focus is on Levels I and II in Clinical Care Medicine; and 2) Products developed for battlefield treatment of Combat Casualties & Combat Trauma, focusing on delivery of Levels III and IV of care. For areas 1 and 2, there are two primary acquisition strategies. The first is to test and evaluate commercially-developed medical product candidates in managed trials for ultimate Food and Drug Administration (FDA) approval. Partnerships with commercial developers ensure that products of military interest are available for procurement across the DoD, Federal Government, and commercial market. During development, DoD end users are included in the process to the extent possible. The second			

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2015 Navy		Date: March 2014
Appropriation/Budget Activity 1319 / 5	R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>	Project (Number/Name) 0933 / <i>Medical/Dental Equipment Dev</i>
strategy is to drive the development process with DoD program investments. This process involves developing in-house or industrial prototypes in government-managed programs to meet military and regulatory requirements for production and fielding. Both strategies promote advanced preparation of procurement plans in line with the product availability. Major Medical Development programs falling in these categories are: MOVES and MOVES anesthesia module (Equipment), Dengue vaccine, and Infusible Haemostatic-Phase I Clinical Trials (Pharmaceuticals/Biologics). The Third Product Area (Knowledge/Concepts) is focused on the introduction of technologies, techniques, and procedures that alter medical practice and standards of care. These primarily require early involvement of the senior leadership of military medicine, in that the result of the program is modification of concepts of operations, policy, and/or doctrine. These are often much smaller; Medical Development Program examples include Navy/USMC Medical Planning Requirement Assessment and Crisis Action Planning Tool Transition. Programs such as System for Objective Decision-Making on Timing of Wound Closure involve both material and knowledge solutions. <u>E. Performance Metrics</u> Maintaining Scheduled Milestones/Demonstration Events for individualized project/product roadmap. Ensuring dependencies across multiple efforts are maintained on schedule and are primary metrics.		

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2015 Navy	Date: March 2014
--	-------------------------

Appropriation/Budget Activity 1319 / 5	R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>	Project (Number/Name) 0933 / <i>Medical/Dental Equipment Dev</i>
--	--	--

MALARIA	FY 2013				FY 2014				FY 2015				FY 2016				FY 2017				FY 2018				FY 2019			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Malaria Vaccine Research																												
Adenovector Manufacturing																												
Pre-Investigational New Drug and Toxicological Study	Milestone ▲																											
Preparation of Materials for trials	Milestone ▲																											
Clinical Trial		Milestone																										

2015DON - 0604771N - 0933

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2015 Navy	Date: March 2014
--	-------------------------

Appropriation/Budget Activity 1319 / 5	R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>	Project (Number/Name) 0933 / <i>Medical/Dental Equipment Dev</i>
--	--	--

MIGRAINES	FY 2013				FY 2014				FY 2015				FY 2016				FY 2017				FY 2018				FY 2019			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Complete IRB Process																												
Complete Enrollment of 400 Subjects with Migraine at MTFs and VA facilities	Milestone																											
Analyze Data and Submit Findings to FDA				Milestone																								
FDA Review and Follow-On				Milestone																								

2015DON - 0604771N - 0933

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2015 Navy	Date: March 2014
--	-------------------------

Appropriation/Budget Activity 1319 / 5	R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>	Project (Number/Name) 0933 / <i>Medical/Dental Equipment Dev</i>
--	--	--

USMC SUICIDE	FY 2013				FY 2014				FY 2015				FY 2016				FY 2017				FY 2018				FY 2019			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
psychological Autopsy Study- Full Report with Conclusions and Risk Checklist																												
Impact of USMC Suicide on Family Survivors- Recommendations for Postvention Efforts	Milestone																											
Marine Resiliency					Milestone																							

2015DON - 0604771N - 0933

UNCLASSIFIED

PE 0604771N: *Medical Development*
Navy

R-1 Line #133

Project (Number/Name)	Start Date	End Date	Status	Manager	Budget (USD)	Actual Cost (USD)	Progress (%)	Risk Level	Notes
101/Alpha	2023-01-15	2023-03-31	Completed	J. Doe	150,000	148,500	100	Low	Exceeded budget by 1.5%
102/Beta	2023-02-01	2023-05-15	In Progress	A. Smith	220,000	180,000	82	Medium	Minor delays in procurement
103/Gamma	2023-03-10	2023-06-30	On Hold	M. Chen	95,000	0	0	High	Waiting for client approval
104/Delta	2023-04-01	2023-07-31	Planned	S. Kim	310,000	0	0	Medium	Initial planning phase
105/Epsilon	2023-05-01	2023-08-31	On Hold	L. Garcia	180,000	0	0	Low	Resource allocation pending
106/Zeta	2023-06-01	2023-09-30	Planned	K. Lee	275,000	0	0	Medium	Market research ongoing
107/Eta	2023-07-01	2023-10-31	Planned	H. Patel	190,000	0	0	Low	Vendor selection in progress
108/Theta	2023-08-01	2023-11-30	Planned	B. Wong	240,000	0	0	Medium	Concept development phase
109/Iota	2023-09-01	2023-12-31	Planned	F. Adams	160,000	0	0	Low	Initial requirements gathering
110/Kappa	2023-10-01	2024-01-31	Planned	C. Brown	200,000	0	0	Medium	Feasibility study underway

0933 / Medical/Dental Equipment Dev

[illegible]

2015DON - 0604771N - 0933

UNCLASSIFIED

PE 0604771N: *Medical Development*
Navy

R-1 Line #133

Project (Number/Name)	0933 / Medical/Dental Equipment Dev
------------------------------	-------------------------------------

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2015 Navy										Date: March 2014		
Appropriation/Budget Activity 1319 / 5					R-1 Program Element (Number/Name) PE 0604771N / Medical Development				Project (Number/Name) 9999 / Congressional Adds			
COST (\$ in Millions)	Prior Years	FY 2013	FY 2014	FY 2015 Base	FY 2015 OCO #	FY 2015 Total	FY 2016	FY 2017	FY 2018	FY 2019	Cost To Complete	Total Cost
9999: Congressional Adds	34.814	28.962	19.000	-	-	-	-	-	-	-	-	82.776
Quantity of RDT&E Articles	0.000	-	-	-	-	-	-	-	-	-		
# The FY 2015 OCO Request will be submitted at a later date.												
Note None												
A. Mission Description and Budget Item Justification Congressional Adds												
B. Accomplishments/Planned Programs (\$ in Millions)								FY 2013	FY 2014			
Congressional Add: Military Dental Research FY 2013 Accomplishments: All the Navy Military Dental Research projects are underway. FY13 research efforts included a number of continuation projects from FY12. These efforts include the following accomplishments: Surveillance of crano-facial injuries, dental disease non-battle injuries and oral/facial disease in military personnel; evaluation of immune response associated with maxillofacial bone regeneration; Development substitutes for restoration of skin in facial wounds to improve functional and aesthetic outcomes; and development of antimicrobial/antibiofilm agents to reduce bacterial burden in order to optimize acute care of combat facial wounds. FY 2014 Plans: Continue research efforts for Surveillance of crano-facial injuries, dental disease non-battle injuries and oral/facial disease in military personnel; evaluation of immune response associated with maxillofacial bone regeneration; development of substitutes for restoration of skin in facial wounds to improve functional and aesthetic outcomes; and development of antimicrobial/antibiofilm agents to reduce bacterial burden in order to optimize acute care of combat facial wounds.								5.992	6.000			
Congressional Add: Wound Care Research (transferred from Defense Health Program) FY 2013 Accomplishments: The Wound Care Research Program is a comprehensive effort which continues to develop novel diagnostics and treatments to enhance the care of the wounded warfighter. The program has developed a computer algorithm to predict wound outcomes and has prepared a submission to the FDA for								12.983	13.000			

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2015 Navy		Date: March 2014
Appropriation/Budget Activity 1319 / 5	R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>	Project (Number/Name) 9999 / <i>Congressional Adds</i>
B. Accomplishments/Planned Programs (\$ in Millions)		
permission to initiate a first-in-man clinical trial. This trial is expected to significantly enhance the care of and improve wound healing in wounded warfighters. FY 2014 Plans: Continue to develop novel diagnostics and treatments to enhance the care of the wounded warfighter. Congressional Add: NAMRU Research FY 2013 Accomplishments: The NAMRU is a comprehensive effort including coordinated projects designed to enhance detection and control strategies for tropical diseases and emerging infections in the areas of responsibility of the three OCONUS Naval Medical Research Units, SE Asia, Africa and the Middle East, and South and Central America. Products will be directed at primary detection and/or control of specific disease but the development and execution of these products will provide the secondary benefit of opportunity to detect other infectious diseases. FY 2014 Plans: N/A	FY 2013	FY 2014
	9.987	-
Congressional Adds Subtotals	28.962	19.000
C. Other Program Funding Summary (\$ in Millions)		
N/A		
Remarks		
D. Acquisition Strategy		
None		
E. Performance Metrics		
Not required for Congressional adds.		